{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:17:37Z","timestamp":1788380257088,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T00:00:00Z","timestamp":1342569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s00280-012-1929-4","type":"journal-article","created":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T20:41:27Z","timestamp":1342644087000},"page":"399-405","source":"Crossref","is-referenced-by-count":228,"title":["Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer"],"prefix":"10.1007","volume":"70","author":[{"given":"Yosuke","family":"Togashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Masago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satohiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Fukudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Ikemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Katsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,18]]},"reference":[{"key":"1929_CR1","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497\u20131500","journal-title":"Science"},{"key":"1929_CR2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129\u20132139","journal-title":"N Engl J Med"},{"key":"1929_CR3","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/cncr.21033","volume":"103","author":"AM Omuro","year":"2005","unstructured":"Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103:2344\u20132348","journal-title":"Cancer"},{"key":"1929_CR4","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cncr.24877","volume":"116","author":"YJ Lee","year":"2010","unstructured":"Lee YJ, Choi HJ, Kim SK, Chang J, Moon JW, Park IK, Kim JH, Cho BC (2010) Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 116:1336\u20131343","journal-title":"Cancer"},{"key":"1929_CR5","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2006.06.6126","volume":"24","author":"DM Jackman","year":"2006","unstructured":"Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Janne PA, Johnson BE (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517\u20134520","journal-title":"J Clin Oncol"},{"key":"1929_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/JCO.2008.21.0963","volume":"27","author":"N Dhruva","year":"2009","unstructured":"Dhruva N, Socinski MA (2009) Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 27:31\u201332","journal-title":"J Clin Oncol"},{"key":"1929_CR7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-010-0128-6","volume":"99","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Pao W, Wu N, Miller VA, Lassman AB (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99:283\u2013286","journal-title":"J Neurooncol"},{"key":"1929_CR8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/JTO.0b013e3181d899bb","volume":"6","author":"A Hata","year":"2011","unstructured":"Hata A, Kaji R, Fujita S, Katakami N (2011) High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thorac Oncol 6:653\u2013654","journal-title":"J Thorac Oncol"},{"key":"1929_CR9","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","volume":"13","author":"C Grommes","year":"2011","unstructured":"Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB (2011) \u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13:1364\u20131369","journal-title":"Neuro Oncol"},{"key":"1929_CR10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/JTO.0b013e3181b62572","volume":"4","author":"T Katayama","year":"2009","unstructured":"Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, Hatooka S, Sueda T, Hida T, Yatabe Y, Mitsudomi T (2009) Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4:1415\u20131419","journal-title":"J Thorac Oncol"},{"key":"1929_CR11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1620\/tjem.214.359","volume":"214","author":"T Fukuhara","year":"2008","unstructured":"Fukuhara T, Saijo Y, Sakakibara T, Inoue A, Morikawa N, Kanamori M, Nakashima I, Nukiwa T (2008) Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med 214:359\u2013363","journal-title":"Tohoku J Exp Med"},{"key":"1929_CR12","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/JTO.0b013e3181dab0dd","volume":"5","author":"Y Togashi","year":"2010","unstructured":"Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M (2010) Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 5:950\u2013955","journal-title":"J Thorac Oncol"},{"key":"1929_CR13","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00280-011-1555-6","volume":"67","author":"T Masuda","year":"2011","unstructured":"Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N (2011) Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 67:1465\u20131469","journal-title":"Cancer Chemother Pharmacol"},{"key":"1929_CR14","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00280-011-1691-z","volume":"68","author":"Y Togashi","year":"2011","unstructured":"Togashi Y, Masago K, Fukudo M, Tsuchido Y, Okuda C, Kim YH, Ikemi Y, Sakamori Y, Mio T, Katsura T, Mishima M (2011) Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 68:1089\u20131092","journal-title":"Cancer Chemother Pharmacol"},{"key":"1929_CR15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0731-7085(02)00014-6","volume":"29","author":"HK Jones","year":"2002","unstructured":"Jones HK, Stafford LE, Swaisland HC, Payne R (2002) A sensitive assay for ZD1839 (Iressa) in human plasma by liquid\u2013liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. J Pharm Biomed Anal 29:221\u2013228","journal-title":"J Pharm Biomed Anal"},{"key":"1929_CR16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchromb.2005.01.027","volume":"819","author":"M Zhao","year":"2005","unstructured":"Zhao M, Hartke C, Jimeno A, Li J, He P, Zabelina Y, Hidalgo M, Baker SD (2005) Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr, B: Anal Technol Biomed Life Sci 819:73\u201380","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"1929_CR17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1570-0232(03)00356-8","volume":"793","author":"M Zhao","year":"2003","unstructured":"Zhao M, He P, Rudek MA, Hidalgo M, Baker SD (2003) Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chromatogr, B: Anal Technol Biomed Life Sci 793:413\u2013420","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"1929_CR18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jchromb.2006.10.046","volume":"848","author":"AR Masters","year":"2007","unstructured":"Masters AR, Sweeney CJ, Jones DR (2007) The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr, B: Anal Technol Biomed Life Sci 848:379\u2013383","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"1929_CR19","doi-asserted-by":"crossref","unstructured":"Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M, Hagiwara K (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65:7276\u20137282","DOI":"10.1158\/0008-5472.CAN-05-0331"},{"key":"1929_CR20","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","volume":"64","author":"T Kosaka","year":"2004","unstructured":"Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919\u20138923","journal-title":"Cancer Res"},{"key":"1929_CR21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1929_CR22","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1200\/JCO.2005.03.145","volume":"23","author":"CJ Langer","year":"2005","unstructured":"Langer CJ, Mehta MP (2005) Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23:6207\u20136219","journal-title":"J Clin Oncol"},{"key":"1929_CR23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1582-4934.2009.00991.x","volume":"14","author":"L Paz-Ares","year":"2010","unstructured":"Paz-Ares L, Souli\u00e8res D, Melez\u00ednek I, Moecks J, Keil L, Mok T, Rosell R, Klughammer B (2010) Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 14:51\u201369","journal-title":"J Cell Mol Med"},{"key":"1929_CR24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","volume":"23","author":"MA Fabian","year":"2005","unstructured":"Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329\u2013336","journal-title":"Nat Biotechnol"},{"key":"1929_CR25","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/annonc\/mdg250","volume":"14","author":"K Nakagawa","year":"2003","unstructured":"Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14:922\u2013930","journal-title":"Ann Oncol"},{"key":"1929_CR26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","volume":"8","author":"MH Cohen","year":"2003","unstructured":"Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8:303\u2013306","journal-title":"Oncologist"},{"key":"1929_CR27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-007-0494-8","volume":"61","author":"N Yamamoto","year":"2008","unstructured":"Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y, Tamura T (2008) Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50\u20138231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 61:489\u2013496","journal-title":"Cancer Chemother Pharmacol"},{"key":"1929_CR28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","volume":"10","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10:461\u2013466","journal-title":"Oncologist"},{"key":"1929_CR29","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2006.10.0677","volume":"25","author":"ER Gerstner","year":"2007","unstructured":"Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25:2306\u20132312","journal-title":"J Clin Oncol"},{"key":"1929_CR30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1078-0432.CCR-10-1934","volume":"17","author":"MA Elmeliegy","year":"2011","unstructured":"Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF (2011) Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17:89\u201399","journal-title":"Clin Cancer Res"},{"key":"1929_CR31","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/dji238","volume":"97","author":"T Mukohara","year":"2005","unstructured":"Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Janne PA (2005) Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185\u20131194","journal-title":"J Natl Cancer Inst"},{"key":"1929_CR32","first-page":"1115","volume":"141","author":"RD Zhang","year":"1992","unstructured":"Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ (1992) Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 141:1115\u20131124","journal-title":"Am J Pathol"},{"key":"1929_CR33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF01052723","volume":"20","author":"DJ Stewart","year":"1994","unstructured":"Stewart DJ (1994) A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 20:121\u2013139","journal-title":"J Neurooncol"},{"key":"1929_CR34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00023210-200216050-00005","volume":"16","author":"P Davey","year":"2002","unstructured":"Davey P (2002) Brain metastases: treatment options to improve outcomes. CNS Drugs 16:325\u2013338","journal-title":"CNS Drugs"},{"key":"1929_CR35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1097\/JTO.0b013e318219ab87","volume":"6","author":"B Weber","year":"2011","unstructured":"Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L, Nexo E, Meldgaard P (2011) Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 6:1287\u20131289","journal-title":"J Thorac Oncol"},{"key":"1929_CR36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(06)70443-4","volume":"5","author":"B Gleissner","year":"2006","unstructured":"Gleissner B, Chamberlain MC (2006) Neoplastic meningitis. Lancet Neurol 5:443\u2013452","journal-title":"Lancet Neurol"},{"key":"1929_CR37","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1634\/theoncologist.2011-0101","volume":"16","author":"G Lombardi","year":"2011","unstructured":"Lombardi G, Zustovich F, Farina P, Della Puppa A, Manara R, Cecchin D, Brunello A, Cappetta A, Zagonel V (2011) Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist 16:1175\u20131188","journal-title":"Oncologist"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1929-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1929-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1929-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T02:27:49Z","timestamp":1561948069000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1929-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,18]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1929"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1929-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,18]]}}}